Discovery of a new series of [1,2,4]triazolo[4,3-a]quinoxalines as dual phosphodiesterase 2/phosphodiesterase 10 (PDE2/PDE10) inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 23, Issue 3, 2013, Pages 785-790

  Andrés, José Ignacio ^a   Buijnsters, Peter ^a   De Angelis, Meri ^a   Langlois, Xavier ^a   Rombouts, Frederik ^a   Trabanco, Andrés A ^a   Vanhoof, Greet ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

Neurological disorders; PDE10 inhibitors; PDE2 inhibitors; Triazoloquinoxalines

Indexed keywords

1 ARYL 4 METHYL(1,2,4)TRIAZOLO[4,3-A]QUINOXALINE DERIVATIVE; PHOSPHODIESTERASE; PHOSPHODIESTERASE 10; PHOSPHODIESTERASE INHIBITOR; SPLEEN EXONUCLEASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; DRUG TRANSPORT; MALE; NONHUMAN; PROTEIN EXPRESSION; RAT; STRUCTURE ACTIVITY RELATION;

ANIMALS; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 2; DRUG DISCOVERY; ENZYME ACTIVATION; INHIBITORY CONCENTRATION 50; MALE; MOLECULAR STRUCTURE; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES; QUINOXALINES; RATS; RATS, WISTAR;

RATTUS;

EID: 84872327016     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2012.11.077     Document Type: Article

References (22)

1. M. Conti, and J. Beavo Annu. Rev. Biochem. 76 2007 481
2. F.S. Mennitti, W.S. Faraci, and C.J. Schmidt Nat. Rev. Drug Disc. 5 2006 660
3. M. Conti Mol. Endocrinol. 14 2000 1317
4. S.H. Soderling, and J.A. Beavo Curr. Opin. Cell Biol. 12 2000 174
5. C. Mehats, C.B. Andersen, M. Filopanti, S.L. Jin, and M. Conti Trends Endocrinol. Metab. 13 2002 29
6. W.C. Van Staveren, H.W. Steinbusch, M. Markerink-Van Ittersum, D.R. Repaske, M.F. Goy, J. Kotera, K. Omori, J.A. Beavo, and J. De Vente J. Comp. Neurol. 467 2003 566
7. N. Yanaka, Y. Kurosawa, K. Minami, E. Kawai, and K. Omori Biosci. Biochem. 67 2003 973
8. S.H. Soderling, S.J. Bayuga, and J.A. Beavo Proc. Natl. Acad. Sci. U.S.A. 96 1999 7071
9. K. Fujishige, J. Kotera, H. Michibata, K. Yuasa, S. Takebayashi, K. Okumura, and K. Omori J. Biol. Chem. 274 1999 18438
10. K. Loughney, P.B. Snyder, L. Uher, G.J. Rosman, K. Ferguson, and V.A. Florio Gene 234 1999 109
11. A. Blokland, R. Schreiber, and J. Prickaerts Curr. Pharm. Des. 12 2006 2511
12. J. Prickaerts, J. de Vente, W. Honig, H.W. Steinbusch, and A. Blokland Eur. J. Pharmacol. 436 2002 83
13. Y. Xu, H.-T. Zhang, and J.M. O'Donnell Neurobiol. Depress. 2012 419
14. V. Lakics, E.H. Karran, and F.G. Boess Neuropharmacology 59 2010 367
15. J.A. Siuciak, D.S. Chapin, J.F. Harms, L.A. Lebel, S.A. McCarthy, L. Chambers, A. Shrikhande, S. Wong, F.S. Menniti, and C.J. Schmidt Neuropharmacology 51 2006 386
16. S.M. Grauer, V.L. Pulito, R.L. Navarra, L. Rachel, M.P. Kelly, C. Kelley, R. Graf, B. Langen, S. Logue, J. Brennan, L. Jiang, E. Charych, U. Egerland, F. Liu, K.L. Marquis, M. Malamas, T. Hage, T.A. Comery, and N.J. Brandon J. Pharmacol. Exp. Ther. 331 2009 574
17. C. Giampà, D. Laurenti, S. Anzilotti, G. Bernardi, F.S. Menniti, and F.R. Fusco PLoS ONE 5 2010 e13417
18. M. Giorgi, G. Melchiorri, V. Nuccetelli, V. D'Angelo, A. Martorana, R. Sorge, V. Castelli, G. Bernardi, and G. Sancesario Neurobiol. Dis. 43 2011 293
19. C. Rundfeldt, K. Socala, and P. Wlaz J. Neural Transm. 117 2010 1319
20. Stange, H.; Langen, B.; Egerland, U.; Hoefgen, N.; Priebs, M.; Malamas, M. S.; Erdei, J.; Ni, Y. PCT Int. Appl. WO2010054253, May 14, 2010.
21. Stange, H.; Langen, B.; Egerland, U.; Hoefgen, N.; Priebs, M.; Malamas, M. S.; Erdei, J. J.; Ni, Y. PCT Int. Appl. WO2010054260, May 14, 2010.
22. While we were elaborating this manuscript a patent application describing closely related derivatives as PDE2 and/or PDE10 inhibitors has been published. Lankau, H.-J.; Langen, B.; Grunwald, C.; Höfgen, N.; Stange, H.; Dost, R.; Egerland, U. PCT Int. Appl. WO2012104293, August 9, 2012.